How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective

As the world continues to feel the impact of COVID-19, the biopharmaceutical industry is working around the clock to identify and develop safe and effective vaccines to prevent infection, while also...
Read More
The 2020 We Work for Health Champion Awards showcase the best of our industry

We are living through an extraordinary moment as COVID-19 continues to spread across the United States. During this time, frontline and essential workers across industries have bravely stepped up to...
Read More
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access...
Read More
Summer reading in the age of COVID-19

As the summer of 2020 starts to creep to a close, America’s biopharmaceutical research companies are working around the clock to identify new treatments to reduce COVID-19 infection and vaccines, to...
Read More
Systemic racism is as real as any disease, and our industry is not immune

This month, PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in the Informer and the AfroAmerican, DC-based, Black-owned newspapers. This public...
Read More
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA found...
Read More
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...
Read More
Supporting access to vaccines for Part D beneficiaries

Today, in honor of National Immunization Awareness Month, we’ll take a look at how Medicare Part D supports access to critical vaccines and strengthens public health. Vaccines represent some of the...
Read More
The patient perspective navigating COVID-19

As PhRMA members work around the clock to combat COVID-19, the pandemic has had a tremendous impact around the globe. But for those patients who are currently impacted by a health care condition,...
Read More
Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines

A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...
Read More
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights an ...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More